Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pyrotinib Maleate Combined With Trastuzumab Plus Aromatase Inhibitor in the First-line Treatment of Advanced HER2-positive/HR-positive Breast Cancer Phase II Study

NCT04088110 is registered in ClinicalTrials.gov with Fuzhou General Hospital as lead sponsor.

NCT NCT04088110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04088110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pyrotinib Maleate Combined With Trastuzumab Plus Aromatase Inhibitor in the First-line Treatment of Advanced HER2-positive/HR-positive Breast Cancer Phase II Study
Lead sponsor
Fuzhou General Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2019
Completion date
November 30, 2023
Enrollment
77 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female, breast diseases, her2-positive breast cancer, hormone receptor positive malignant neoplasm of breast, hormone receptor positive tumor, metastatic breast cancer